|
Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation’s current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs – Alzheimer’s disease, Huntington’s disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs.
Recent Releases
Jun 11, 2009
Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 'CONNECTION' Trial of Dimebon in Patients With Alzheimer's Disease
Jun 4, 2009
Medivation to Present at 8th Annual Needham Life Sciences Conference
more »
|
 Briefcase
 Download Library
 Email Alerts
 RSS News Feeds
For Investors
investors@medivation.com
For Media
media@medivation.com
Transfer Agent
American Stock Transfer
and Trust Company
59 Maiden Lane
New York, NY 10038
(800) 937-5449
www.amstock.com
|
